Luka Živković

Luka Živković

Auto-generated profile, based on publicly available information

Luka Živković

Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Circulation
Verified
Journal Article
Closed access
SPSavvina Prapiadou
Savvina Prapiadou
LŽLuka Živković
Luka Živković
BTBarbara Thorand
Barbara Thorand
MGMarc J. George
Marc J. George
Sander van der LaanSander van der Laan
Sander van der Laan
Marios K GeorgakisMarios K Georgakis
Marios K Georgakis
BACKGROUND: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects. METHODS: Leveraging data from 522 681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6R (IL-6 receptor) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization, we assessed its effects on 3281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3301). Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease. For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions. RESULTS: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 (C-X-C motif chemokine ligand 10) were associated with risk of coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease, with up to 67% of the effects of genetically downregulated IL-6 signaling on these end points mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher CXCL10 expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling. CONCLUSIONS: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ–inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.

1 May 2022 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
LŽLuka Živković
Luka Živković
Yaw AsareYaw Asare
Yaw Asare
JBJürgen Bernhagen
Jürgen Bernhagen
MDMartin Dichgans
Martin Dichgans
Marios K GeorgakisMarios K Georgakis
Marios K Georgakis
Background: The CCL2 (CC-chemokine ligand 2)/CCR2 (CC-chemokine receptor 2) axis governs monocyte recruitment to atherosclerotic lesions. Genetic and epidemiological studies show strong associations of CCL2 levels with atherosclerotic disease. Still, experimental studies testing pharmacological inhibition of CCL2 or CCR2 in atheroprone mice apply widely different approaches and report variable results, thus halting clinical translation. Methods: We systematically searched the literature for studies employing pharmacological CCL2/CCR2 blockade in atheroprone mice and meta-analyzed their effects on lesion size and morphology. Results: In a meta-analysis of 14 studies testing 11 different agents, CCL2/CCR2 blockade attenuated atherosclerotic lesion size in the aortic root or arch ( g =−0.75 [−1.17 to −0.32], P =6×10 − 4 ; N=171/171 mice in experimental/control group), the carotid ( g =−2.39 [−4.23 to −0.55], P =0.01; N=24/25), and the femoral artery ( g =−2.38 [−3.50 to −1.26], P =3×10 − 5 ; N=10/10). Furthermore, CCL2/CCR2 inhibition reduced intralesional macrophage accumulation and increased smooth muscle cell content and collagen deposition. The effects of CCL2/CCR2 inhibition on lesion size correlated with reductions in plaque macrophage accumulation, in accord with a prominent role of CCL2/CCR2 signaling in monocyte recruitment. Subgroup analyses showed comparable efficacy of different CCL2- and CCR2-inhibitors in reducing lesion size and intralesional macrophages. The quality assessment revealed high risk of detection bias due to lack of blinding during outcome assessment, as well as evidence of attrition and reporting bias. Conclusions: Preclinical evidence suggests that pharmacological targeting of CCL2 or CCR2 might lower atherosclerotic lesion burden, but the majority of existing studies suffer major quality issues that highlight the need for additional high-quality research.

18 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LŽLuka Živković
Luka Živković
Yaw AsareYaw Asare
Yaw Asare
JBJürgen Bernhagen
Jürgen Bernhagen
MDMartin Dichgans
Martin Dichgans
Marios K GeorgakisMarios K Georgakis
Marios K Georgakis
Rationale: The CC-chemokine ligand-2 (CCL2)/ CC-chemokine receptor-2 (CCR2) axis governs monocyte recruitment to atherosclerotic lesions. Coherent evidence from experimental studies employing genetic deletion of CCL2 or CCR2 and human epidemiological studies support a causal involvement of the CCL2/CCR2 axis in atherosclerosis. Still, preclinical studies testing pharmacological inhibition of CCL2 or CCR2 in atheroprone mice apply widely different approaches and report inconsistent results, thus halting clinical translation. Objective: To systematically review and meta-analyze preclinical studies pharmacologically targeting the CCL2/CCR2 axis in atherosclerosis in an effort to inform the design of future trials. Methods and Results: We identified 14 studies testing CCL2/CCR2 inhibition using 11 different pharmacological agents in mouse models of atherosclerosis. In meta-analyses, blockade of CCL2 or CCR2 attenuated atherosclerotic lesion size in the aortic root or arch ( g =-0.75 [-1.17 to -0.32], p=6×10 −4 ; N=171/171 mice in experimental/control group), the carotid ( g =-2.39 [-4.23 to -0.55], p=0.01; N=24/25) and the femoral artery ( g =-2.38 [-3.50 to -1.26], p=3×10 −5 ; N=10/10). Furthermore, CCL2/CCR2 inhibition reduced intralesional macrophage accumulation and increased smooth muscle cell content and collagen deposition, consistent with a plaque-stabilizing effect. While there was heterogeneity across studies, the effects of CCL2/CCR2 inhibition on lesion size correlated with reductions in plaque macrophage accumulation, in accord with a prominent role of CCL2/CCR2 signaling in monocyte recruitment. Subgroup analyses revealed similar efficacy of both CCL2- and CCR2-inhibiting approaches across different atherosclerosis models in reducing lesion size and intralesional macrophage accumulation, but stronger atheroprotective effects in carotid and femoral arteries, as compared to the aorta. Conclusions: Pharmacological targeting of CCL2 or CCR2 lowers atherosclerotic lesion burden and confers plaque stability in mice across different vascular territories, drug candidates, and models of atherosclerosis. Our findings in conjunction with recent human data highlight the translational potential of targeting the CCL2/CCR2 axis in atherosclerosis and can inform future clinical trials. Subject codes: atherosclerosis, inflammation, vascular biology, translational studies

25 September 2026 in Science Advances
Verified
Journal Article
Closed access
LŽLuka Živković
Luka Živković
RBRoya Batool
Roya Batool
JLJulian Louma
Julian Louma
PAPaulo Alabarse
Paulo Alabarse
YLYingle Li
Yingle Li
Marios K GeorgakisMarios K Georgakis
Marios K Georgakis
Omics technologies enable deep profiling of human atherosclerosis but have mostly been applied in small studies lacking integration with other data modalities. AtherOMICS is a biobanking project linking multiomic atherosclerotic plaque phenotyping with blood biobanking, in vivo imaging, and clinical data. Here, we present the study protocol and show pilot results that demonstrate technical feasibility. Since August 2022, 246 patients scheduled to undergo carotid or femoral endarterectomy at Ludwig-Maximilians-Universität Klinikum (Munich, Germany), have been enrolled (median age, 73 years; 32% female), with recruitment ongoing. Plaques undergo systematic histological characterization of lipid core, calcification, intraplaque hemorrhage, fibrous cap, macrophages, and smooth muscle cells. Single-nucleus RNA sequencing ( n = 17) has confirmed macrophages as the dominant intraplaque cell type, whereas paired plaque and plasma affinity–based proteomics ( n = 88) quantified 2841 shared proteins showing low plaque-plasma correlation (median ρ = 0.10). Cross-modality image integration [histology, ex vivo magnetic resonance imaging (MRI), in vivo MRI, and computed tomography angiography] proved feasible. Together, AtherOMICS enables multimodal characterization of human atherosclerosis aiming for the discovery of athero-specific drug targets, molecular signatures of atheroprogression, and noninvasive biomarkers of plaque vulnerability.

18 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LŽLuka Živković
Luka Živković
RBRoya Batool
Roya Batool
JLJulian Louma
Julian Louma
PAPaulo Alabarse
Paulo Alabarse
YLYingle Li
Yingle Li
Marios K GeorgakisMarios K Georgakis
Marios K Georgakis
Omics technologies enable deep profiling of human atherosclerosis, but have mostly been applied in small studies lacking integration with other data modalities. AtherOMICS is a biobanking project linking multi-omic atherosclerotic plaque phenotyping with blood biobanking, in vivo imaging, and clinical data. Since August 2022, 246 patients scheduled to undergo carotid or femoral endarterectomy at LMU Klinikum (Munich, Germany), have been enrolled (median age 73 years, 32% female). Plaques undergo systematic histological characterization of lipid core, calcification, intraplaque hemorrhage, fibrous cap, macrophages, and smooth muscle cells. Single-nuclei RNAseq (n=17) has highlighted macrophages as the dominant intraplaque cell type, whereas paired plaque and plasma affinity-based proteomics (n=88) quantified 2,841 shared proteins showing low plaque-plasma correlation (median ρ=0.10). Cross-modality image integration (histology, ex vivo MRI, in vivo MRI, CTA) proved feasible. Taken together, AtherOMICS enables multimodal characterization of human atherosclerosis aiming for the discovery of athero-specific drug targets, molecular signatures of atheroprogression, and non-invasive biomarkers of plaque vulnerability.

29 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SMStefan Mayrhofer
Stefan Mayrhofer
LŽLuka Živković
Luka Živković
YLYingle Li
Yingle Li
RBRoya Batool
Roya Batool
JLJulian Louma
Julian Louma
Marios K GeorgakisMarios K Georgakis
Marios K Georgakis
Background and Aims: Quantifying arterial inflammation can augment risk stratification and drug development in atherosclerosis. While perivascular adipose tissue (PVAT) density, captured as fat attenuation index (FAI) on CT angiography (CTA), is an emerging biomarker of coronary inflammation, it remains unclear whether this concept extends to carotid atherosclerosis. Methods: Using routine CTA data from hospital-based stroke cohorts, we developed a pipeline to quantify attenuation metrics of PVAT surrounding the distal common and proximal internal carotid arteries. We compared PVAT metrics between culprit and contralateral non-culprit plaques in patients with symptomatic carotid atherosclerosis and between culprit plaques and control carotid segments from patients without symptomatic atherosclerosis. In patients undergoing carotid endarterectomy, we assessed associations of CTA-derived PVAT metrics with histological and proteomic markers of plaque inflammation and stability. Results: Across 107 patients with symptomatic carotid atherosclerosis (75.5±8.7 years; 63% men), PVAT attenuation metrics did not show significant differences between culprit and contralateral non-culprit lesions (all p>0.2). We also found no evidence for higher PVAT attenuation in culprit lesions, when compared to arteries of patients without symptomatic atherosclerosis. In 82 patients undergoing endarterectomy, pre-operative CTA-derived metrics of PVAT attenuation showed no significant correlations with CD68+ macrophage areas in excised plaques (r -0.11 to 0.07, all p>0.3). Similarly, no PVAT attenuation metrics were associated with thinner fibrous cap or higher plaque levels of pro-inflammatory cytokines (IL-6, TNF). Conclusions: In contrast to coronary atherosclerosis, carotid PVAT attenuation was not associated with symptomatic culprit lesions or histological and molecular markers of plaque inflammation and vulnerability. Structured Graphical Key Question: Can perivascular adipose tissue (PVAT) attenuation on CT, proposed as a marker of coronary artery inflammation, also capture atherosclerotic plaque inflammation and vulnerability in the carotid arteries? Key Finding: In 107 patients with carotid atherosclerosis-associated stroke, PVAT attenuation did not differ between culprit and contralateral non-culprit lesions and was not associated with histopathological or molecular markers of plaque inflammation and vulnerability. Take-home Message: PVAT attenuation did not capture local carotid plaque inflammation or vulnerability in this cohort, questioning the transferability of this CT-based marker from coronary to carotid atherosclerosis.